The current therapeutic algorithm for chronic spontaneous urticaria (CSU), endorsed by the
international guideline, entails treatment escalation from second‐generation H1 …

Objective Immunoglobulin E (IgE) and its receptor, FcɛRI, importantly contribute to the
pathophysiology of chronic spontaneous urticaria (CSU). Recent findings point to a possible …

Chronic urticaria (CU) is a common skin condition characterized by the recurrence of
wheals, with or without angioedema, which lasts for at least 6 weeks. Owing to its pruritus …

Importance Omalizumab is indicated for the management of chronic idiopathic urticaria
(CIU)(also known as chronic spontaneous urticaria) in adolescents and adults with …

Background Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of
wheals and/or angioedema for≥ 6 weeks. Omalizumab is a monoclonal anti‐IgE antibody …

abstract IgE and mast cells play a pivotal role in various allergic diseases, including asthma,
allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody …

Introduction: Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological
condition characterized by itchy wheals and/or angioedema of continuous or intermittent …

Urticaria and angioedema are very common. Management of chronic urticaria subtypes,
which usually persist for many years, is challenging. Recent years have demonstrated that …

Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population.
CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible …

Background Omalizumab is the only biological agent approved for patients with chronic
spontaneous urticaria (CSU), but no biomarker is well established for predicting clinical …